PLGA nanoparticles containing Intimin-Flagellin fusion protein for E. coli O157:H7 nano-vaccine

Abianeh, Hossein Samiei; Nazarian, Shahram; Sadeghi, Davoud; Razgi, Amir Sajjad Hojjati; Samarin, Mojtaba Zafarmand

doi:10.1016/j.jim.2023.113517

Cited by 3 publications

(1 citation statement)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among various polymeric NPs, PLGA NPs are the most extensively investigated as vaccine carriers, largely due to their US FDA approval and licensing for medical applications [73,[153][154][155]]. An early study has shown that PLGA NPs loaded with indocyanine green (ICG) and a toll-like-receptor-7 agonist (R837), combined with photothermal therapy (PTT), can elicit a greater anti-tumor immune response compared to traditional adjuvants [156].…”

Section: Polymeric Nanoparticlesmentioning

confidence: 99%

The quest for nanoparticle-powered vaccines in cancer immunotherapy

Sun,

Zhao,

et al. 2024

J Nanobiotechnol

View full text Add to dashboard Cite

Despite recent advancements in cancer treatment, this disease still poses a serious threat to public health. Vaccines play an important role in preventing illness by preparing the body's adaptive and innate immune responses to combat diseases. As our understanding of malignancies and their connection to the immune system improves, there has been a growing interest in priming the immune system to fight malignancies more effectively and comprehensively. One promising approach involves utilizing nanoparticle systems for antigen delivery, which has been shown to potentiate immune responses as vaccines and/or adjuvants. In this review, we comprehensively summarized the immunological mechanisms of cancer vaccines while focusing specifically on the recent applications of various types of nanoparticles in the field of cancer immunotherapy. By exploring these recent breakthroughs, we hope to identify significant challenges and obstacles in making nanoparticle-based vaccines and adjuvants feasible for clinical application. This review serves to assess recent breakthroughs in nanoparticle-based cancer vaccinations and shed light on their prospects and potential barriers. By doing so, we aim to inspire future immunotherapies for cancer that harness the potential of nanotechnology to deliver more effective and targeted treatments. Graphical abstract

show abstract

Section: Polymeric Nanoparticlesmentioning

confidence: 99%

The quest for nanoparticle-powered vaccines in cancer immunotherapy

Sun,

Zhao,

et al. 2024

J Nanobiotechnol

View full text Add to dashboard Cite

show abstract

Therapeutic efficacy of SipD/LptD-specific IgY entrapped in alginate nanoparticles against Salmonella Typhimurium infection

zafarmand-samarin,

Nazarian,

Aghaie

et al. 2024

Heliyon

View full text Add to dashboard Cite

Nanovaccines to combat drug resistance: the next-generation immunisation

Manju,

Raj,

Ranjini

et al. 2023

Futur J Pharm Sci

View full text Add to dashboard Cite

Background The present review envisages the role of nanovaccines to combat the global challenges of antimicrobial resistance. Nanovaccines are a novel formulation comprised of nanomaterials coupled with an immunogenic component to elicit the immune response and provide protection against the desired infectious disease. The nanovaccines with unique physicochemical properties can be more efficient against targeting the desired tissues in the body, aids in prolong circulation to promote antigen-presenting cells to act upon the target antigens. Main content The present review envisages the development of nanovaccines against antimicrobial-resistant pathogens. The use of nanovaccines can exhibit potent antigenicity with prolonged retention and controlled release to induce both cell- and antibody-mediated responses. Nanovaccines usage is still in the early stages and can be next-generation immunisation for prophylactic and therapeutic efficiency. The future development of nanovaccines against multi-drug-resistant pathogens can explore new avenues. Based on these facts, the present review is designed from the previously reported scientific studies and compiled with the fact that nanovaccines can revolutionise vaccine strategies. The articles were extracted from reputed databases like PubMed, Scopus, and ESCI. The size and conjugating chemistry of nanomaterials can be beneficial in developing novel multi-nanovaccine formulations that can target pools of antimicrobial resistance mechanisms. Conclusion Overall, the nanovaccines can form one of the best effective modes of targeting multi-drug-resistant pathogens. The nanovaccines can stimulate the innate immune response and generate effective immune-therapeutic novel formulation against infectious pathogens. Based on these facts and considerations, the present article makes an alarming call to develop nanovaccines to counter multi-drug resistance.

show abstract

PLGA nanoparticles containing Intimin-Flagellin fusion protein for E. coli O157:H7 nano-vaccine

Cited by 3 publications

References 25 publications

The quest for nanoparticle-powered vaccines in cancer immunotherapy

The quest for nanoparticle-powered vaccines in cancer immunotherapy

Therapeutic efficacy of SipD/LptD-specific IgY entrapped in alginate nanoparticles against Salmonella Typhimurium infection

Nanovaccines to combat drug resistance: the next-generation immunisation

Contact Info

Product

Resources

About